A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma

BACKGROUND: Compared with the standard of care with sunitinib, avelumab plus axitinib can increase progression-free survival in the first-line of advanced renal cell carcinoma (RCC), but the economic effect of the treatment is unknown. The purpose of the research was to evaluate the cost-effectivene...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Front Pharmacol
Main Authors: Lu, Peiyao, Liang, Weiting, Li, Jiahao, Hong, Yanming, Chen, Zhuojia, Liu, Tao, Dong, Pei, Huang, Hongbing, Zhang, Tiantian, Jiang, Jie
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2020
Teme:
Pharmacology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7225300/
https://ncbi.nlm.nih.gov/pubmed/32457618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.00619
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki